摘要目的 初步比较派姆单抗与纳武单抗治疗晚期恶性肿瘤的疗效和安全性.方法 回顾分析2017-2018年间在我院接受派姆单抗和纳武单抗治疗的50例晚期恶性肿瘤患者资料,其中派姆单抗组26例,纳武单抗组24例.x2检验两组不良反应差异,Kaplan-Meier生存分析.结果 中位无进展生存期派姆单抗组213d,纳武单抗组146 d(P＞0.05).纳武单抗转氨酶增高(63％:23％,P＜0.05)、甲状腺功能减退(12％:0％,P＜0.05),但派姆单抗口腔黏膜炎较高(0％:15％,P＜0.05).中位总生存期派姆单抗组579 d,纳武单抗组238 d(P＞0.05).结论 派姆单抗组和纳武单抗组初步显示疗效差异不明显,但不良反应略有差异.

abstractsObjective To preliminarily compare the efficacy and safety of Pembrolizumab and Nivolumab in the treatment of advanced malignant tumors.Methods Clinical data of 50 patients diagnosed with advanced malignant tumors treated with Pembrolizumab and Nivolumab from January 2017 to August 2018 in our hospital were retrospectively analyzed.All patients were divided into the Pembrolizumab (n =26) and Nivolumab groups (n =24).The incidence of adverse reactions was statistically compared between two groups by using x2 test.The survival analysis was performed by using Kaplan-Meier method.Results The median progression-free survival in the Pembrolizumab group was 213 d,and 146 d in the Nivolumab group (P＞0.05).The incidence of aminotransferase elevation and hypothyroidism in the Nivolumab group was significantly higher than that in the Pembrolizumab group (63％ vs.23％,12％ vs.0％,both P＜0.05),whereas the incidence of oral mucositis in the Nivolumab group was 0％,significantly lower than 15％ in the Pembrolizumab group (P＜0.05).The median overall survival time in the Pembrolizumab group was 579 d,and 238 d in the Nivolumab group (P＞0.05).Conclusion Clinical efficacy does not significantly differ,whereas the incidence of adverse reactions slightly differs between the Pembrolizumab and Nivolumab groups.